ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

DeVita Suggest “Overlay Consortium” as Outreach Mechanism for Southern California, Other Areas

September 28, 1984

Adjuvant Chemo Improves Survival In Early Lung Cancer

July 30, 2004

“Alternative” Is Misleading Term, President’s Cancer Panel Writes To Healy

February 5, 1993

NCI FY94 Budget By Mechanism Under House, Senate Mark

September 24, 1993

NCI Says More Phase Trials Needed In Cancer Prevention, Nutrition

April 18, 1986

NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use

December 7, 1984